PubMed Health⌕ Search

PubMed · 15017346

Invasive fetal testing.

Abstract

PURPOSE OF REVIEW: Research on prenatal diagnosis and invasive fetal testing has continued at a rapid pace. Several studies that will have a profound impact on the way prenatal care will be provided to pregnant women have been published in the literature during the last year. These publications will be reviewed and their impact described. RECENT FINDINGS: The main areas of interest in the recent literature covered in this review are first-trimester screening for aneuploidy, recent information on loss rates due to amniocentesis and chorionic villus sampling, and current work on invasive fetal therapy. SUMMARY: It appears that first-trimester screening is at least comparable if not superior in efficacy to second-trimester serum screening. This will be a test that will be utilized increasingly by both low and high-risk patients for aneuploidy. Of utility to a much smaller number of patients, invasive fetal therapy for meningomyelocele repair, twin-to-twin transfusion syndrome and fetal cardiac malformations is being evaluated in a scientifically more rigorous manner.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Robert H Ball. 2004. Invasive fetal testing.. https://doi.org/10.1097/00001703-200404000-00011

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Operator experience and sample quality in genetic amniocentesis.

OBJECTIVE: We sought to relate the frequency of maternal cell contamination in amniotic fluid samples that were submitted to a single laboratory for cytogenetic analysis to the experience and training of the physician who performed the amniocentesis. STUDY DESIGN: We reviewed the database of a single cytogenetics laboratory to compare the number of amniocenteses that were performed annually per physician to the rate of maternal cell contamination in genetic amniocentesis samples. Only samples that resulted in a 46 XY male karyotype were studied so that maternal cell contamination could be identified as having occurred when the karyotype revealed > or = 1 cell with 2 X chromosomes. Samples were categorized as being submitted by a physician who submitted > or = 50 or more samples annually versus < 50 samples to this laboratory. The frequency of maternal cell contamination was compared with annual operator volume with 2 x 2 tables and analyzed by chi-squared testing. RESULTS: Between 2000 and 2004, the laboratory received 6332 mid-trimester amniotic fluid samples that generated a male karyotype result. Fourteen of 2081 samples (0.67%) that were submitted by physicians who submitted < 50 samples grew > or = 1 46 XX cells, compared with 8 of 4251 samples (0.19%; chi-squared, 9.47; degrees of freedom, 1; P = .0021). CONCLUSION: Maternal cell contamination occurs more frequently in genetic amniocentesis samples that are obtained by physicians who perform < 50 genetic amniocenteses annually.

Amniocentesis↗

Screening for Down syndrome: practice patterns and knowledge of obstetricians and gynecologists.

OBJECTIVE: To assess obstetricians' practice patterns and knowledge regarding screening for Down syndrome. METHODS: A questionnaire was mailed to 1,105 American College of Obstetricians and Gynecologists Fellows and Junior Fellows in 2004. RESULTS: Sixty percent of questionnaires were returned. Statistical analyses were limited to the 532 practicing obstetricians. Greater than 80% felt their training and experience qualified them to counsel patients about genetic issues in pregnancy. However, 45% rated their residency training regarding prenatal diagnosis as barely adequate or nonexistent. American College of Obstetricians and Gynecologists publications were rated by 86% as an important source of information on genetic counseling. Seventy-eight percent of practitioners counsel all obstetric patients about risks for fetal aneuploidy, and 67% provide counseling for heritable genetic abnormalities. Although the majority (99%) offer second-trimester Down syndrome screening, only 55% also offer first-trimester screening for Down syndrome. Almost one half (49%) use the quad screen, and 6% offer integrated first- and second-trimester screening. The majority (88%) routinely offer amniocentesis to patients who are at elevated risk for genetic abnormalities, whereas 44% also offer chorionic villus sampling. Few (2%) perform chorionic villus sampling. CONCLUSION: Most obstetricians manage patients at risk for fetal genetic abnormalities according to American College of Obstetricians and Gynecologists educational materials. This survey identified deficiencies related to Down syndrome screening, including a limited number of practitioners performing chorionic villus sampling and physicians' own perception that training regarding genetic counseling should be improved. Educational strategies are needed to address these deficiencies before first-trimester screening programs are widely implemented. LEVEL OF EVIDENCE: III.

Amniocentesis↗

Incorporating first-trimester Down syndrome studies into prenatal screening: executive summary of the National Institute of Child Health and Human Development workshop.

The National Institute of Child Health and Human Development (NICHD), the Society for Maternal-Fetal Medicine, and the American College of Obstetricians and Gynecologists (ACOG), cosponsored a workshop on December 16-17, 2004, to discuss the evidence for first-trimester Down syndrome screening and to explore the effects of combining first- and second-trimester screening, given the results of recent U.S. trials. The experts evaluated the evidence for offering first-trimester screening to provide individual risk assessment for Down syndrome. First-trimester screening has been demonstrated to provide efficient Down syndrome risk assessment, with a detection rate of 84% (95% confidence interval 80-87%), which is clinically comparable to the second-trimester quadruple screen at a fixed false-positive rate of 5%. The participants at the workshop concluded that at this time there is sufficient evidence to support implementing first-trimester Down syndrome risk assessment in obstetric practice in the United States, provided that certain requirements can be met. These requirements include training and quality control standards for first-trimester nuchal translucency measurement and laboratory assays, access to chorionic villus sampling, and appropriate counseling regarding screening options.

Amniocentesis↗